Enhancing CAR T Cell Homing Through Glycoengineering
通过糖工程增强 CAR T 细胞归巢
基本信息
- 批准号:10577107
- 负责人:
- 金额:$ 22.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-09 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAdoptive Cell TransfersAdoptive TransferAffinityAllogenicAntigen TargetingAntigensApplications GrantsBone MarrowBone neoplasmsCell LineCell TherapyCell physiologyCellsCellular immunotherapyClinicalClinical DataClinical TrialsCytotoxic T-LymphocytesDataDevelopmentDiseaseDoseEffectivenessEffector CellEndothelial CellsEngineeringEngraftmentFoundationsFucoseFucosyltransferaseFutureGlycoengineeringGoalsHematologic NeoplasmsHematopoietic stem cellsHomeHomingHumanImmuneImmunotherapeutic agentImmunotherapyIn VitroInfusion proceduresKnowledgeLeukemic CellLeukocyte ElastaseLigandsMalignant - descriptorMalignant NeoplasmsMalignant lymphoid neoplasmMarrowMediatingMembraneMembrane GlycoproteinsMethodsMyeloid LeukemiaNormal tissue morphologyParentsPatient CarePatientsPhase I Clinical TrialsPredispositionProcessProteinase 3ProteinsPublishingRefractoryRegulatory T-LymphocyteRelapseResearchRoleSafetySelectinsSiteSolid NeoplasmStem cell transplantSurfaceT cell therapyT-Cell Homing ReceptorsT-LymphocyteTestingTherapeuticTissuesToxic effectTumor AntigensTumor TissueUmbilical Cord BloodUmbilical Cord Blood TransplantationWorkXenograft procedureacute myeloid leukemia cellantitumor effectblood productcancer cellcancer immunotherapycancer therapycell killingchimeric antigen receptorchimeric antigen receptor T cellsclinical efficacyclinical trial enrollmentcytotoxicend of life caregraft vs host diseaseimprovedin vivoinnovationleukemiamouse modelneoplastic cellnovelnovel therapeutic interventionparticipant enrollmentpatient prognosispre-clinicalresponsestandard of carestem cellssuccesssugartreatment strategytumorvector
项目摘要
The importance of T cell homing to the tumor site is a critical aspect of the anti-tumor immune cellular
response. Most of the recent advances in cancer immunotherapy have focused on generating potent tumor
specific T cells and overcoming tumor-induced T cell inhibition and tolerance. However, a rate-limiting step to
establishing efficacious cellular therapy for the treatment of malignancies is the lack of T cell homing to the
tumor site. To circumvent this obstacle, we investigated fucosylation as a mechanism to enhance cytotoxic T
lymphocyte (CTL) homing. Fucosylation, a process mediated by fucosyltransferases, adds fucose sugar
groups to cell surface glycoproteins, increasing their affinity to selectins on tumor cells, endothelial cells, and
within inflamed tissues. Our preclinical work using ex vivo fucosylation of tumor-specific polyclonally-expanded
CTL and regulatory T cells (Treg) showed enhanced CTL homing to bone marrow and tumor sites, and Treg
homing to graft-versus-host disease involved tissues, respectively. Furthermore, fucosylation of cord blood
(CB) products enhanced the homing and engraftment of CB stem cells to marrow in patients with hematologic
malignancies undergoing CB transplants. What remains unknown is whether fucosylation of CAR T cells will
enhance their homing into tumor tissue. Without this knowledge, the effectiveness of CAR T cells as an
immunotherapeutic strategy for the treatment of cancer will likely remain limited.
Our long-term objective is to develop effective cellular immunotherapy for cancer. In this proposal, we
will investigate the role of fucosylation in the setting of acute myeloid leukemia (AML), using a fucosylated CAR
T cell approach (i.e. fucosylated 8F4-CAR T cells) which targets an antigen that our group discovered, PR1.
We hypothesize that immunotherapy using fucosylated 8F4-CAR T cells will inhibit AML in vivo, with minimal
off-target toxicity. In our first aim, we will study the effects of ex vivo fucosylation on 8F4-CAR T cell efficacy
and safety, and in the second aim, we will determine whether engineering 8F4-CAR T cells to endogenously
express fucosyltransferase VII will enhance their anti-tumor activities. We will employ an AML xenograft
mouse model in both aims, and will elucidate the mechanisms by which fucosylation augments T cell activity.
Our proposed research is significant, in that fucosylation is expected to enhance not only T cell homing and
entry into tumor sites, but also their cytolytic machinery, thereby improving their efficacy. Furthermore, since
the engineering of an adequate dose of tumor-specific effector cells is at times a limiting step to adoptive
cellular therapy, fucosylation will allow for the engineering and infusion of fewer tumor-targeting T cells, as
more fucosylated T cells are expected to home favorably to the malignant milieu. Underscored by the fact that
stem cell fucosylation has already demonstrated safety and efficacy clinically, we believe our innovative
approach may greatly facilitate the effectiveness of T cell therapy in AML as well as other malignant diseases,
and could transform our current approach to cellular immunotherapy.
T细胞归巢到肿瘤部位的重要性是抗肿瘤免疫细胞的一个关键方面
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gheath Al-Atrash其他文献
Gheath Al-Atrash的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gheath Al-Atrash', 18)}}的其他基金
Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion
通过预处理自体淋巴细胞输注减轻高级别辐射引起的淋巴细胞减少症
- 批准号:
9807793 - 财政年份:2019
- 资助金额:
$ 22.72万 - 项目类别:
Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion
通过预处理自体淋巴细胞输注减轻高级别辐射引起的淋巴细胞减少症
- 批准号:
10017926 - 财政年份:2019
- 资助金额:
$ 22.72万 - 项目类别:
MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC
MD 安德森癌症免疫监测与分析中心 MDA-CIMAC
- 批准号:
10729960 - 财政年份:2017
- 资助金额:
$ 22.72万 - 项目类别:














{{item.name}}会员




